Video

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer (CRC).

Although there have been many advances in the treatment landscape of BRAF-mutant CRC, there is still room for improvement, says Kopetz. Currently, a promising triplet therapy of BRAF, MEK, and EGFR inhibitors is being studied in this population.

In the randomized phase III BEACON study, the triplet of binimetinib, encorafenib, and cetuximab (Erbitux), is being evaluated in patients with metastatic BRAF V600E CRC whose disease has progressed after 1 or 2 prior regimens. Kopetz says that this combination demonstrated a promising response rate of about 48%, with a median progression-free survival of about 8 months.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS